Report of Foreign Issuer (6-k)
June 12 2019 - 12:10PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of
June
2019
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Publication
of a Prospectus
12 June 2019 16:45 BST
Publication of Prospectus
Following a routine technical update of the Company's Euro Medium
Term Note ("EMTN") programme established in 2007, the following
prospectus has been approved by the UK Listing Authority and is
available for viewing:
Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro
Medium Term Note Programme (the "Prospectus").
The last drawdown under the EMTN programme was in
2016.
To view the full document, please paste the following URL into the
address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/0175C_1-2019-6-12.pdf
A copy of the above Prospectus has been submitted to the National
Storage Mechanism and will shortly be available for inspection
at:
http://www.morningstar.co.uk/uk/NSM
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please
visit
astrazeneca.com
and
follow us on Twitter
@
AstraZeneca
.
|
Media
Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203
749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203
749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301
518 4122
|
|
Matt
Kent
|
BioPharma
|
+44 203
749 5906
|
|
Jennifer
Hursit
|
Other
|
+44
203 749 5762
|
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharma
(cardiovascular; metabolism)
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharma
(respiratory; renal)
|
+44 203
749 5716
|
|
Josie
Afolabi
|
Other
medicines
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance,
fixed income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate
access, retail investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
12 June
2019
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Apr 2023 to Apr 2024
